Comparison of the effect of electrosurgery with cryosurgery in the treatment of sebaceous hyperplasia, seborrheic keratosis, cherry angioma and skin tag

Evaluation of efficacy and safety of electrosurgery in comparison with cryosurgery in patients with sebaceous hyperplasia, seborrheic keratosis, cherry angioma and skin tag: A controlled randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211210053344N1

Enrollment

128

Registered

2021-12-28

Start date

2022-01-21

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: sebaceous hyperplasia. Condition 2: seborrheic keratosis. Condition 3: cherry angioma. Condition 4: skin tag. Other specified follicular disorders Seborrheic keratosis Hemangioma of skin and subcutaneous tissue Other hypertrophic disorders of the skin

Interventions

Intervention 1: Intervention group 1: For patients in this group, electrosurgery is done at the first session and repeated 4 weeks later if necessary (maximum 2 sessions). Electrosurgery is performed

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Confirmation of diagnosis with a clinical examination by a dermatologist Age 18 to 70 years

Exclusion criteria

Exclusion criteria: Infection of the lesion site History of keloid Pregnancy and Lactation Malignancy Immunosuppression For electrosurgery: having an intracardiac device For cryosurgery: cold intolerance, history of Raynaud's phenomenon, vesiculobullous diseases and superficial sensory involvement

Design outcomes

Primary

Measure	Time frame
Lesion size. Timepoint: At the beginning of the study, 2 weeks, 1 month and 3 months later. Method of measurement: with a ruler.;The rate of improvement. Timepoint: 2 weeks, 1 month and 3 months after the beginning. Method of measurement: based on evaluation of a blind dermatologist.	—

Secondary

Measure	Time frame
Safety. Timepoint: 2 weeks, 1 month and 3 months after the beginning. Method of measurement: based on side effects of the treatment (clinical evaluation).;Tolerability. Timepoint: 2 weeks, 1 month and 3 months after the beginning. Method of measurement: based on Investigator Assessment of Tolerability scale.;Satisfaction. Timepoint: 2 weeks, 1 month and 3 months after the beginning. Method of measurement: based on Caregiver treatment satisfaction (CTS) questionnaire.	—

Measure

Time frame

Safety. Timepoint: 2 weeks, 1 month and 3 months after the beginning. Method of measurement: based on side effects of the treatment (clinical evaluation).;Tolerability. Timepoint: 2 weeks, 1 month and 3 months after the beginning. Method of measurement: based on Investigator Assessment of Tolerability scale.;Satisfaction. Timepoint: 2 weeks, 1 month and 3 months after the beginning. Method of measurement: based on Caregiver treatment satisfaction (CTS) questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAfsaneh Sadeghzadeh Bazargan

Iran University of Medical Sciences

afsaneh.sadeghzadeh@yahoo.com+98 21 6651 7341

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026